Teva says its generic Adderall shortage will last another 2 to 3 months (NYSE:TEVA) | Seeking Alpha
Teva Offers Drugs Valued at $23 Billion to End Opioid Suits - Bloomberg
Teva Pharmaceuticals - Wikipedia
Teva Agrees to Purchase Rimsa in $2.3 Billion Deal
Teva to lay off 25% of workforce, suspends dividend - BNN Bloomberg
Teva shares jump in Tel Aviv after report of up to 10,000 job cuts | The Times of Israel
Future Teva CEO Seeks to 'Formulate Clear Strategy' - YouTube
/cloudfront-us-east-2.images.arcpublishing.com/reuters/CCBS56SBRRKUDM7JEVVE3UOQEE.jpg "Teva Pharmaceutical meets forecasts, but 2023 outlook disappoints | Reuters")
Teva Pharmaceutical meets forecasts, but 2023 outlook disappoints | Reuters
Ex-Teva Chairman, Blockchain Investor Accused of Pump-and-Dump Scheme - WSJ
Teva CEO Calls 'Trough' Revenues Consequence of Patent Expirations - YouTube
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
Teva: Reportedly Planning Thousands of Layoffs in the U.S. | Fortune
Teva Cites 'Havoc' as It Takes Drug Label Spat to Supreme Court (1)
Justice Dept reportedly may file charges in its generic-drug probe by year-end
Teva: Now What? | Barron's
Teva Pharma's Short Sellers Double Down as Legal Woes Drag On - Bloomberg
Teva Hit With New Lawsuit Over Proposed Korlym Drug Copy
Teva Pharmaceuticals Names Kare Schultz As New CEO | Fortune
Teva's Trouble Was Predicted. Path to Recovery Not as Clear - Bloomberg
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Teva Considering Cutting up to 10,000 Jobs: Bloomberg
Teva's Adderall Shortage Seen Continuing Into March (TEVA) - Bloomberg
Teva (TEVA) Agrees to $225 Million Texas Opioid Settlement, AG Says - Bloomberg
CVS, Teva, Allergan and Endo reach $878 million deal with Florida over the opioid crisis - STAT
Teva CEO Resigns; Dividend Cut Should Be Next - Bloomberg
